Parasite lipids against asthma or diabetes

November 11, 2003

Dutch research has demonstrated that lipids from the parasite schistosoma can inhibit human immune responses. This property makes the lipids interesting for a possible new treatment of diseases such as asthma and diabetes where the immune system responds inappropriately.

During her doctoral research, Desiree van der Kleij discovered that lipids from the parasite schistosoma steer the development of the immune system in a certain direction. Cells from the innate immune system, so-called dendritic cells, respond to these lipids. During this response these cells can initiate the development of so-called regulatory T-cells. These regulatory T-cells subsequently suppress the activity of other cells in the immune system.

The researcher discovered that one of the lipids with this steering effect on dendritic cells contains a fatty acid that does not occur in humans. She also demonstrated that this specific lipid of the parasite activates a specific receptor on dendritic cells. Once the receptor had been blocked, it was found that regulatory T-cells no longer developed after dendritic cells had been stimulated with the parasite lipid.

Diseases such as diabetes and asthma are caused by inappropriate immune responses to certain substances. Molecules which can inhibit the immune responses, such as the lipids of schistosomes, could be used to suppress these errant responses. The use of lipids from schistosomes for this purpose will be investigated in a follow-up study funded by the Netherlands Organisation for Scientific Research.

In the immune system, dendritic cells detect the presence of pathogens in the body. These cells then direct the development of immune responses so that a type of immune response develops which is appropriate to combat the pathogen present. The pathogen could be a bacteria, but equally a virus or a parasite.

Schistosomes are parasitic worms. More than 200 million people worldwide are infected with the worm. The majority of these people live in Africa and South America. The worms can survive in their host for years. Although infected persons develop an immune response during an infection, the parasite significantly suppresses the activity of the immune system in people who are chronically infected with these worms. This suppression is probably caused by regulatory T-cells.
-end-
For further information please contact Dr Desiree van der Kleij (Department of Parasitology, Leiden University Medical Center), tel. 31-71-526-5066, e-mail: d.van_der_kleij@lumc.nl. The doctoral thesis was defended on 5 November 2003 at Leiden University. Dr Van der Kleij's supervisors were Prof. A.M. Deelder (Leiden University Medical Center) and Prof. A.G.M. Tielens (Utrecht University) and her assistant supervisor was Dr M. Yazdanbakhsh (Leiden University Medical Center).

The research was funded by the Netherlands Organisation for Scientific Research.

Netherlands Organization for Scientific Research

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.